Schedule 13D ownership disclosure

CHECKPOINT THERAPEUTICS INC

Common Stock, $0.0001 Par Value · CUSIP: 162828206

Event date: 2024-12-31

Filing-level shares
6,903,749.00
Percent of class
13.5%
  • Fortress Biotech, Inc.Reported CIK 0001429260

    Shares: 6,903,749.00 · Class: 13.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-25-000920
Form type
SCHEDULE 13D/A
Filer
Checkpoint Therapeutics, Inc.
CIK
CIK 1651407
Filed
Jan 03, 2025
Reporting period
Dec 31, 2024
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub